04:41 PM EDT, 08/29/2025 (MT Newswires) -- PDS Biotechnology ( PDSB ) filed a registration statement Friday for the potential sale of up to $200 million of securities from time to time in one or more offerings.

The filing covers common and preferred stock, debt securities, warrants, units, and rights to purchase common stock, preferred stock, debt securities, or units.

Net proceeds are expected to be used for the development and commercialization of the company's product candidates and for general corporate purposes.